$INAB
IN8bio, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$1.08
▲+0.93%+$0.010
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateIN8bio, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is INAB up today? It is at $1.08 (+0.93%). See the catalyst behind the move, real-time alerts the moment INAB spikes, and full due diligence on INAB — key stats, earnings, dilution and insider activity. Free.
Be first to know when $INAB makes an unusual move. Create a free account to track $INAB, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on INAB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for INAB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystIN8BIO, INC.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Fairbairn Emily Director | Sold (automatic/other) | -725K 7.4% of company | sold 99% | 4K | n/a | May 27, 26 |
Fairbairn Emily Director | Acquired (grant/award) | +725K 7.4% of company | added 100% | 729K | $1000K at $1.38 | Dec 22, 25 |
Roemer Alan S. Director | Acquired (grant/award) | +36K 0.4% of company | added 100% | 50K | $50K at $1.38 | Dec 22, 25 |
Brandt Peter C. Director | Acquired (grant/award) | +72K 0.7% of company | added 100% | 95K | $100K at $1.38 | Dec 22, 25 |
Rochlin Kate Officer | Acquired (grant/award) | +7K 0.07% of company | added 100% | 9K | $10K at $1.38 | Dec 22, 25 |
Ho William Tai-Wei Officer | Acquired (grant/award) | +36K 0.4% of company | added 43% | 121K | $50K at $1.38 | Dec 22, 25 |
Mccall Patrick Officer | Acquired (grant/award) | +7K 0.07% of company | added 100% | 9K | $10K at $1.38 | Dec 22, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on INAB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for INAB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
INAB last traded at $1.08, up 0.93% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
IN8bio, Inc. Common Stock (INAB) is next expected to report earnings on Thursday, November 5, 2026, about 46 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The INAB Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged INAB 0 times in the last 30 days.
INAB (IN8bio, Inc. Common Stock) trades on XNAS, with a market cap of about $11M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge INAB for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$INAB discussion
Sign in to ask a question or join the discussion.